Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.

Successful treatment of severe mechanical mitral valve thrombosis with tissue plasminogen activator in a 7-month-old infant.

Updating clinical endpoint definitions.

Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.

Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.

Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery.

Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination.

Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

Common atrium and pulmonary vascular disease.

Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.

Pulmonary hypertension in children with sickle cell disease.

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.